PTGS2 and metabolic dysfunction-associated steatohepatitis: Pharmacological or genetic inhibition of PGE2 production has been shown to attenuate the inflammatory response in various inflammation models15–17 and the inhibition of COX-2 has been shown to inhibit NASH development in type 2 diabetic rats18, arguing in favor of a pro-inflammatory impact of PGE2.